Sonnet BioTherapeutics Holdings, Inc.
SONN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $5 | $5 | $3 | $4 |
| - Cash | $0 | $2 | $5 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5 | $3 | -$2 | $4 |
| Revenue | $0 | $0 | $1 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | -$0 | -$0 | -$1 | -$0 |
| % Margin | – | – | -88.6% | – |
| EBITDA | -$4 | -$4 | -$3 | -$3 |
| % Margin | – | – | -282.7% | – |
| Net Income | -$4 | -$3 | -$3 | -$3 |
| % Margin | – | – | -316.1% | – |
| EPS Diluted | -0.95 | -0.89 | -1.56 | -4.81 |
| % Growth | -6.7% | 42.9% | 67.6% | – |
| Operating Cash Flow | -$2 | -$2 | -$3 | -$3 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$2 | -$3 | -$3 |